Clinical trial · Observational
Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer
Comparing the Diagnostic Role of 18F-FDG PET/MRI and of 18F-FDG PET/CT Among Patients With Gastric Cancer：A Randomized Controlled Trial
NCT03015298CI-TRIAL-00025431unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The results of PET/MRI and PET/CT in each recruited gastric cancer patients will be compared.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer Stage | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT | Device | — | UNRESOLVED |
| PET/MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Gastric cancer
- description
- Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
- interventionNames
- Device: PET/MRI
- Device: PET/CT
Primary outcomes (1)
- measure
- The results of the PET/MRI and PET/CT examination
- timeFrame
- 3 days
- description
- Two experienced radiologists independently assess the TNM staging of gastric cancer using preoperative PET/MRI and PET/CT images
Secondary outcomes (7)
- measure
- Histopathological diagnosis
- timeFrame
- 5 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histological diagnosis of gastric cancer 2. No previous treatment history for gastric cancer 3. Without complications of obstruction,bleeding and so on 4. Without severe diabetes,the levels of blood glucose \<6.2 mmol/L . 5. No cardiac pacemarker,never stimulator or other metal substitute materials in vivo. Exclusion Criteria: 1. With other neoplastic disease. 2. Suffering acute inflammatory disease 3. History of chemo-radiotherapy 4. Suffering prostate hyperplasia,glaucoma
References
Publications (0)
Data not yet available
No reference posted for this study.